GH Form 4: Director Manuel Hidalgo Medina reports 232-share RSU vesting
Rhea-AI Filing Summary
Insider reported acquisition of shares from restricted stock units. Manuel Hidalgo Medina, a director of Guardant Health, acquired 232 shares on 08/17/2025 at a reported price of $0, increasing his direct common stock holdings to 3,016 shares. The filing also reports the conversion/vesting of 232 restricted stock units on the same date, leaving 8,121 restricted stock units (reported as derivative securities) beneficially owned in a direct capacity. The RSU award was granted on July 17, 2024 and vests over four years, with 25% vesting at the one-year anniversary and the remaining 75% vesting monthly over the next three years. The form was signed via attorney-in-fact on 08/18/2025.
Positive
- 232 restricted stock units vested and converted to common stock on 08/17/2025, increasing direct holdings.
- Clear vesting schedule disclosed: grant date July 17, 2024 with four-year vesting (25% at one year, remainder monthly).
- Post-transaction holdings reported: 3,016 shares directly and 8,121 RSU-related derivative interests directly beneficially owned.
Negative
- None.
Insights
TL;DR: Director received vested RSUs converting to 232 shares, modestly increasing direct ownership.
The Form 4 documents a standard vesting event rather than an open-market purchase or sale. The reported 232 shares were acquired with a stated price of $0, consistent with conversion of restricted stock units into common shares. Post-transaction, the reporting person holds 3,016 common shares directly and 8,121 RSU-related derivative interests reported as direct beneficial ownership. This is a routine equity compensation disclosure for a director and appears immaterial to capitalization or control.
TL;DR: Transaction reflects scheduled RSU vesting tied to a 2024 grant, not an unusual insider action.
The filing explicitly notes the RSU grant date of July 17, 2024 and the four-year vesting schedule (25% after one year, remainder monthly over three years). The conversion/vesting on 08/17/2025 aligns with that schedule. The use of an attorney-in-fact signature is documented. From a governance perspective, this is a routine disclosure of compensation-related vesting rather than a signal of non-routine insider trading.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 232 | $0.00 | -- |
| Exercise | Common Stock | 232 | $0.00 | -- |
Footnotes (1)
- The restricted stock unit granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter. Not applicable for Restricted Stock Units.